Leczenie małopłytkowości w okresie noworodkowym – fakty i wątpliwości

*Agata Bojdo¹, Anna Tarasiuk^{1, 2}, Paweł Łaguna³, Monika Pohorecka⁴, Jacek Witwicki¹, Marzena Dębska²

Summary
The authors present the current state of knowledge on the causes, consequences and treatment of thrombocytopenia in the neonatal period. They show the relationship causes of thrombocytopenia with time of its occurrence and maturity of the afflicted newborn child. They also discussed the possibilities and limitations of thrombocytopenia therapy. The essence, quiddity of this publication is to show the difficulty in qualifying for supplementary transfusion of platelets in the absence of evidence of its effectiveness and reports of possible complications.
A preventive and symptomatic transfusion was distinguished, emphasizing the lack of evidence to the causality of the platelet count with the appearing of actual clinical bleeding. The authors noted changes in recommendations designed to reduce the number of platelets as an indication for the adjuvant therapy. They presented and discussed recommendations developed by BCSH (British Committees for Standards in Haematology) in 2004. It was stressed that most of these recommendations were based on the experience and opinions of the experts.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.